Kalos Therapeutics Announces Selection Of New Lead Drug Candidates

Kalos CEO, George Colberg, announced the selection of two new lead drug candidates using their patented ANP (atrial natriuretic peptide) peptides. One of the lead drug candidates is for pancreatic cancer for humans and the other is for epistaxis for equines.

(firmenpresse) - Kalos is globally known for their pioneering approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds. Therefore the announcement of their lead drug candidate, KTH-222, has been hailed as a breakthrough cancer drug capable of besting current treatments in terms of efficacy and simultaneously avoiding the tremendous cascade of side effects typically associated with chemotherapy.

Lead Drug Candidate 1: KTH-222, Pancreatic Cancer

€œBased on extensive work with human cancer cells lines and, more recently, models of human cancer, we have selected KTH-222 for clinical development to treat pancreatic cancer. The data indicates that KTH-222 may be more effective for treating this disease than current therapies while producing fewer adverse side effects€ stated CSO Dr. Michael Kozlowski.

Even without optimizing the dose or the dosing regimen, KTH-222 produced a reduction in tumor growth and has now surpassed that of the standard of care, gemcitabine (Gem), which optimally dosed.

Lead Drug Candidate 2: KTV-111, Animal and Diuretic applications

Clinical data indicates that KTV-111 has an overall diuretic effect comparable to the best current diuretic agents, but that this effect has a longer duration of action and also should produce minimal side effects like our other ANP products. This profile is ideal for some veterinary applications, such as the treatment of EIPH. Kalos is well underway exploring human clinical applications as well.

About Kalos Therapeutics Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates, primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyper proliferative disorders. More information can be found on Kalos'' web site at http://www.kalostherapeutics.com[](http://www.kalostherapeutics.com)

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: alekspressdev
Datum: 15.10.2015 - 05:13 Uhr
Sprache: Deutsch
News-ID 1392340
Anzahl Zeichen: 0

contact information:
Contact person: George Colberg
Town:

San Diego

Phone: 858-552-6890

Kategorie:

Pharmaceuticals & Biotech

Anmerkungen:


Diese Pressemitteilung wurde bisher 219 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Kalos Therapeutics Announces Selection Of New Lead Drug Candidates
"
steht unter der journalistisch-redaktionellen Verantwortung von

Kalos Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Kalos Therapeutics